Esposito Maria Valeria, Aveta Achille, Comegna Marika, Cernera Gustavo, Iacotucci Paola, Carnovale Vincenzo, Taccetti Giovanni, Terlizzi Vito, Castaldo Giuseppe
CEINGE-Biotecnologie Avanzate, 80131 Naples, Italy.
Dipartimento di Neuroscienze, Sezione di Urologia, Università di Napoli Federico II, 80131 Naples, Italy.
J Clin Med. 2020 Nov 27;9(12):3853. doi: 10.3390/jcm9123853.
A wide range of cystic fibrosis (CF)-related conditions are reported in CF carriers, but no study has explored the possibility that such subjects may be affected by cystic fibrosis transmembrane regulator-related disorders (CFTR-RD). No data are available so far on the occurrence of CFTR-RD among CF carriers. We studied 706 CF carriers-first- and second-degree relatives of CF patients that carried the parental mutation; such subjects were divided in two groups: a first group (353 subjects, group A) performed at first only the analysis of the CFTR proband mutation; we retrospectively evaluated the number of cases that had been diagnosed as CFTR-RD based on subsequent symptoms; a second group (353 subjects, group B) performed extensive molecular analysis in absence of any reported symptoms, followed by a clinical evaluation in cases that carry a second mutation; we evaluated the number of cases that prospectively were diagnosed as CFTR-RD. We found seven (2.0%) out of 353 subjects of group A and 24 (6.8%) out of 353 subjects of group B as affected by CFTR-RD (chi square, = 0.002). A percentage of CF carriers are affected by undiagnosed CFTR-RD. Genetic tasting scanning analysis helps to identify CFTR-RD, some of which may benefit from follow-up and specific therapies improving their outcome.
据报道,囊性纤维化(CF)携带者存在多种与CF相关的病症,但尚无研究探讨这些个体可能受囊性纤维化跨膜传导调节因子相关疾病(CFTR-RD)影响的可能性。目前尚无关于CF携带者中CFTR-RD发生率的数据。我们研究了706名CF携带者——携带亲本突变的CF患者的一级和二级亲属;这些个体被分为两组:第一组(353名个体,A组)最初仅对CFTR先证者突变进行分析;我们根据后续症状回顾性评估被诊断为CFTR-RD的病例数;第二组(353名个体,B组)在无任何报告症状的情况下进行广泛的分子分析,对携带第二个突变的病例进行临床评估;我们前瞻性评估被诊断为CFTR-RD的病例数。我们发现A组353名个体中有7名(2.0%)、B组353名个体中有24名(6.8%)受CFTR-RD影响(卡方检验,P = 0.002)。一定比例的CF携带者受未确诊的CFTR-RD影响。基因检测扫描分析有助于识别CFTR-RD,其中一些患者可能受益于随访和特定治疗,从而改善其预后。